Company Overview of Medicago Inc.
Medicago Inc., a clinical-stage biotechnology company, develops novel vaccines and therapeutic proteins to treat various infectious diseases worldwide. The company develops its vaccines based on its proprietary technologies comprising the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidates include H5N1 pandemic influenza VLP vaccine, which has completed a Phase II human clinical trial; and seasonal influenza and H1N1 vaccines. The company’s products under development also comprise non-influenza VLP and rabies vaccine candidates. It has a strategic alliance with Mitsubishi Tanabe Pharma Corporation to develop a Rotavirus vaccine candidate; and res...
1020 Route de l'Église
Quebec, QC G1V 3V9
Founded in 1997
Key Executives for Medicago Inc.
Chief Executive Officer, President and Director
Executive Vice President of Operations
Director of Investor Relations & Communications
Vice-President of Quality Assurance and Quality Control
Vice President of Manufacturing
Compensation as of Fiscal Year 2015.
Medicago Inc. Key Developments
Canadian Government Engages Medicago to Develop Ebola Monoclonal Antibodies
Oct 29 15
Medicago has been awarded a contract by the Public Health Agency of Canada (PHAC) to develop two antibodies to fight the Sudan strain of the Ebola virus. Medicago will produce these antibodies at its facility in Quebec City. In producing this technology, Medicago will demonstrate a Canadian capability to manufacture monoclonal antibodies as part of emergency preparedness and response efforts. The Canadian government and Medicago are now working together on antibodies for the Sudan strain lineage, building on existing work directed at the Zaire strain which is responsible for the ongoing outbreak in West Africa.
Medicago to Build $245 Million Production Facility in Quebec City
May 19 15
Medicago announced that Quebec City will be home to its new production complex. The $245 million project will create 200 new high-skilled jobs by 2019, adding to the team of 180 employees already working at Medicago's Quebec City office and laboratories. The project is expected to generate more than $461 million in direct and indirect economic benefits over the next five years. Medicago chosed Quebec City because of its qualified employees and the access to an experienced workforce, world-class research infrastructure, a dynamic business culture and support from the federal, provincial and municipal governments. Medicago's new complex will be built in Quebec City'sEspace d'innovation D'Estimauville (Estimauville innovation park) and completed by 2019. It will regroup Medicago's head office, research and development activities, and commercial production plant. Medicago's new 44,000 m2 facility will be located on a 90,000 m2 site. It will have the capacity to deliver up to 40 to 50 million doses of quadrivalent seasonal flu vaccines. In addition, work towards developing new products will take place over the upcoming years. Medicago's innovative technology uses plants like miniature factories that can quickly produce large quantities of vaccines or treatments. This technology demonstrated its potential for responding to global pandemics when it produced candidate vaccines for H1N1 in 2009 and H7N9 in 2013 in just 19 days, compared to the several months required to produce vaccines using eggs.
Medicago Inc. Receives Contract by the U.S. Department of Health and Human Services to Explore Alternate Production Methods for Ebola Antibodies
Feb 24 15
Medicago Inc. announced that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services (HHS) for three anti-Ebola virus monoclonal antibodies (mAbs) with expected performance comparable to that of ZMapp, from Mapp Biopharmaceutical. Medicago will manufacture the antibodies in its Quebec City, Canada facility, for a study in non-human primates (NHP). Two of these antibodies were discovered by the Public Health Agency of Canada. This order is the result of a Task Order Request (TOR) that was solicited by BARDA on December 22, 2014. It is part of the Indefinite Delivery/Indefinite Quantity (ID/IQ) contract between Medicago and the Defense Advanced Research Projects Agency (DARPA).
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries